Bio-Thera Solutions & Intas Pharmaceuticals Expand Partnership

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, expanded its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for Canada.

BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha, a pro-inflammatory molecule. 

The reference medicine golimumab has been approved in Canada for several indications, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

“We are pleased to expand our partnership with Accord for BAT2506 by adding Canadian commercialization rights to the partnership,” said Bert Thomas, Senior Vice President of Business Development at Bio-Thera. “Canada is an important market for Bio-Thera, and this partnership is the beginning of a concerted effort to bring our biosimilar products to Canada.”

“Our exclusive commercialization agreement with Bio-Thera strengthens our biosimilar pipeline, a vital component of our North American growth strategy,” said Chrys Kokino, President of North America Accord. “We’re investing heavily in biosimilars through external partnerships plus our own clinical efforts, because we believe in their vast potential to drive patient- and provider-centric solutions.”